• 虚拟现实和增强现实技术在教育、医疗和娱乐领域的应用不断拓展。
  • 随着人口老龄化的加剧,养老服务和健康管理需求日益增长。
  • 随着全球化的深入,跨文化交流和国际合作变得日益重要。
  • 海洋塑料污染问题引起了全球范围内的广泛关注和行动。
  • 太空探索的商业化为航天产业带来了新的增长点。
  • 自动化和机器人技术在提高制造业效率和安全性方面发挥着关键作用。
  • 隐私保护和数据安全在数字化时代变得更加重要。
  • 远程医疗的普及使得医疗服务更加便捷,尤其是在偏远地区。
  • 随着太空探索的商业化,航天产业迎来了新的发展机遇。
  • 电动汽车的快速增长正在推动全球汽车产业的绿色转型。
  • 网络安全问题成为全球关注的焦点,尤其是在个人数据保护方面。
  • 随着太空探索的进展,商业航天领域迎来了新的发展机遇。
  • 气候变化问题再次成为全球关注的焦点。
  • 网络安全成为数字化时代的关键挑战。
  • 在线教育的普及为全球学习者提供了更广泛的学习机会。
  • 在线健身和虚拟健身课程在疫情期间迅速流行。
  • 智能家居设备使日常生活更加便捷,推动了居住环境的智能化。
  • 网络安全漏洞频发,个人信息保护成为公众关注的焦点。
  • 生物技术在医药领域的应用带来了新的突破和挑战。
  • 自动化和机器人技术在提高生产效率和降低成本方面取得显著进展。
  • 全球健康危机加速了医疗保健行业的数字化转型。
  • 海洋塑料污染问题引起了全球范围内的环保行动。
  • 在线教育的普及为全球学习者提供了更多样化的学习资源。
  • 电子竞技的兴起改变了传统体育和娱乐行业的格局。
  • 电子竞技的兴起改变了传统体育和娱乐行业的格局。
  • Neuroendocrine prostate tumors: histologic features and therapy | Greco | Uro-Technology Journal

    Neuroendocrine prostate tumors: histologic features and therapy

    Francesco Greco, Luigi Domanico, Antonino Inferrera, Maurizio Gozo, Francesco Lembo

    Abstract


    Neuroendocrine (NE) tumors of the prostate are rare tumors, that can arise de novo but much more commonly occur after androgen deprivation therapy for prostate adenocarcinoma. NE tumors of the prostate are classified into: adenocarcinoma with NE differentiation, well-differentiated NE tumor/carcinoid, small-cell NE carcinoma, large cell NE carcinoma, adenocarcinoma with Paneth cell NE differentiation and mixed NE carcinoma—acinar adenocarcinoma. IHC plays a vital role and should be approached at two levels. For the issue of confirming NE differentiation, markers for NE differentiation include synaptophysin, chromogranin, and CD56. If there is any uncertainty about the histogenesis, that is, whether a tumor is primary to the prostate, markers for prostatic lineage—PSA, PSAP, PSMA, prostein (p501s), NKX3.1, ERG (by IHC or FISH)—may be used. Actually, platinum-based chemotherapy is commonly administered to patients with pure small cell carcinoma based on small cell lung cancer (SCLC) data and the accumulating data for aggressive variants of castration-resistant prostate cancer (AVPC). This may consist of a combination of carboplatin (or sometimes cisplatin) plus either etoposide (based on SCLC) or a taxane (especially if mixed histology or AVPC features). A combination regimen of cisplatin, etoposide, and doxorubicin has been also investigated but the benefit-risk ratio of the three-drug combination was considered unfavorable. Unfortunately, platinum-based chemotherapy often presents high toxicity and a short overall survival. Results of currently ongoing preclinical and clinical studies are expected to enhance our understanding of these tumors’ underlying biology and guide our efforts toward the development of personalized medicine through targeted diagnostic and therapeutic approaches.


    Keywords: Prostate cancer, neuroendocrine disease, histologic differentiation, systemic therapies




    Subscribe to receive issue release notifications
    and newsletters from journals